ClinicalTrials.gg
RecruitingNCT06726369Updated Oct 13, 2026

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors

A Phase 1 interventional study of MK-6204 (SKB535) for Injection in Advanced Solid Tumors, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 13, 2026Site recruiting status changedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
142
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, nonrandomized, multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MK-6204 as monotherapy in participants with advanced solid tumors.

Read the detailed description

This is an open-label, nonrandomized, multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MK-6204 as monotherapy in participants with advanced solid tumors. The primary objectives are to evaluate the safety and tolerability of MK-6204. The secondary endpoints include PK parameters, ORR, DOR, and immunogenicity of MK-6204. The study will include a Screening Phase, a Treatment Phase, and a Post-treatment Follow up Phase.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • ADC
  • safety
  • tolerability
  • pharmacokinetics
03

In context

Lead sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is the lead sponsor of 55 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Have a or cytologically confirmed advanced/ solid tumor by pathology report and have failed or do not have available standard treatments. The tumor types will be limited to: CRC; Gastric carcinoma or gastroesophageal junction (GEJ) adenocarcinoma; Biliary tract cancer.
  3. Have by 1.1 as assessed by the local site investigator/radiology. Target lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
  4. Have a performance status of 0 or 1 on the Performance Scale.
  5. The participant has provided documented for the study.
  6. Participants who agree to provide sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated.
  7. Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.

Exclusion criteria

Exclusion Criteria:

  1. Active severe digestive disease, including but not limited to complete or incomplete gastrointestinal obstruction, persistent/recurrent vomiting, severe gastrointestinal hemorrhage, gastric or duodenal ulcers, acute gastrointestinal perforation, acute necrotizing pancreatitis, ulcerative enteritis, congenital megacolon, or Crohn's disease.
  2. Participants with a history of interstitial lung disease (ILD) or a history of noninfectious pneumonitis that required , have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  3. Received strong cytochrome P450 () inhibitors or inducers within 2 weeks prior to the first dose of study intervention or within 5 half-lives of drug elimination, whichever is longer.
  4. Received strong breast cancer resistance protein (BCRP) inhibitors within 2 weeks prior to the first dose of study intervention or within 5 half-lives of drug elimination, whichever is longer.
  5. Received prior systemic anticancer therapy including agents within 4 weeks or 5 half-lives, whichever is shorter, before intervention allocation.
  6. Known additional that is progressing or has required active treatment within the past 5 years.
  7. Known active and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (i.e., without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    MK-6204 (SKB535) for Injection

    Several dose levels of MK-6204 (SKB535) for Injection are planned and administered every 3 weeks.

    Drug: MK-6204 (SKB535) for Injection

Interventions

  • DrugMK-6204 (SKB535) for Injection

    MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during the evaluation period and is at least possibly related to study drug.

    Time frame: From the date of first dose until up to 21 days of intervention

  2. Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention.

    Time frame: From the date of first dose until up to 30 days after the last dose of intervention

  3. Serious Adverse Event (SAE)

    An SAE is defined as any serious untoward medical occurrence that meets the pre-specified criteria in the protocol

    Time frame: From the date of first dose until up to 30 days after the last dose of intervention

Secondary outcomes

  1. PK parameter AUC

    PK parameter AUC after single and multiple doses

    Time frame: Through study completion, an average of 2 years

  2. PK parameter Cmax

    PK parameter Cmax after single and multiple doses

    Time frame: Through study completion, an average of 2 years

  3. PK parameter Cmin

    PK parameter Cmin after single and multiple doses

    Time frame: Through study completion, an average of 2 years

  4. Objective response rate (ORR)

    ORR refers to the proportion of participants who have achieved confirmed complete response (CR) or partial response (PR).

    Time frame: Through study completion, an average of 2 years

  5. Duration of response (DOR)

    DOR refers to the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Through study completion, an average of 2 years

  6. Immunogenicity of MK-6204

    ADA incidence

    Time frame: Through study completion, an average of 2 years

07

Study locations

8 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2029, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 10, 2024
StartActual
Dec 12, 2024
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Hunan Cancer Hospital · Changsha, ChinaNot yet recruiting→Recruiting
  • West China Hospital of Sichuan University · Chengdu, ChinaNot yet recruiting→Recruiting
  • Chongqing University Cancer Hospital · Chongqing, ChinaNot yet recruiting→Recruiting
  • Fujian Provincial Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
  • Shanghai East Hospital · Shanghai, ChinaNot yet recruiting→Recruiting
  • Hubei Cancer Hospital · Wuhan, ChinaNot yet recruiting→Recruiting
Show 3 added (3 China)
  • The First Affiliated Hospital of Xiamen University · Xiamen, China
  • Hubei Cancer Hospital · Wuhan, China
  • Linyi Cancer Hospital · Linyi, China
Oct 13, 2026
Enrollment
90→142
Oct 13, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedHave a histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report and have failed or do not have available standard treatments. The tumor types will be limited to: CRC; Gastric carcinoma or gastroesophageal junction (GEJ) adenocarcinoma; Esophageal carcinoma; PancreaticBiliary tract cancer; NSCLC; Cervical carcinoma; Head and Neck squamous cell carcinoma.
Exclusion criteria
  • EditedActive severe digestive disease, including but not limited to complete or incomplete gastric outletgastrointestinal obstruction, persistent/recurrent vomiting, severe gastrointestinal hemorrhage, gastric or duodenal ulcers, acute gastrointestinal perforation, acute necrotizing pancreatitis, ulcerative enteritis, congenital megacolon, or Crohn's disease.
  • EditedKnown additional malignancy that is progressing or has required active treatment within the past 25 years.
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    3 sites added. 6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Hunan Cancer Hospital · Changsha, ChinaNot yet recruiting→Recruiting
    • West China Hospital of Sichuan University · Chengdu, ChinaNot yet recruiting→Recruiting
    • Chongqing University Cancer Hospital · Chongqing, ChinaNot yet recruiting→Recruiting
    • Fujian Provincial Cancer Hospital · Fuzhou, ChinaNot yet recruiting→Recruiting
    • Shanghai East Hospital · Shanghai, ChinaNot yet recruiting→Recruiting
    • Hubei Cancer Hospital · Wuhan, ChinaNot yet recruiting→Recruiting
    Show 3 added (3 China)
    • The First Affiliated Hospital of Xiamen University · Xiamen, China
    • Hubei Cancer Hospital · Wuhan, China
    • Linyi Cancer Hospital · Linyi, China
    Enrollment 90→142
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedHave a histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report and have failed or do not have available standard treatments. The tumor types will be limited to: CRC; Gastric carcinoma or gastroesophageal junction (GEJ) adenocarcinoma; Esophageal carcinoma; PancreaticBiliary tract cancer; NSCLC; Cervical carcinoma; Head and Neck squamous cell carcinoma.
    Exclusion criteria
    • EditedActive severe digestive disease, including but not limited to complete or incomplete gastric outletgastrointestinal obstruction, persistent/recurrent vomiting, severe gastrointestinal hemorrhage, gastric or duodenal ulcers, acute gastrointestinal perforation, acute necrotizing pancreatitis, ulcerative enteritis, congenital megacolon, or Crohn's disease.
    • EditedKnown additional malignancy that is progressing or has required active treatment within the past 25 years.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06726369
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Dec 12, 2024
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Lin Shen
Contact
linshenpku@163.com
010-88196561

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion